Form 8-K - Current report:
SEC Accession No. 0001641172-25-016979
Filing Date
2025-06-27
Accepted
2025-06-27 17:30:37
Documents
14
Period of Report
2025-06-24
Items
Item 3.03: Material Modifications to Rights of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K form8-k.htm   iXBRL 8-K 46997
  Complete submission text file 0001641172-25-016979.txt   256860

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE ptix-20250624.xsd EX-101.SCH 3515
3 XBRL DEFINITION FILE ptix-20250624_def.xml EX-101.DEF 26546
4 XBRL LABEL FILE ptix-20250624_lab.xml EX-101.LAB 36500
5 XBRL PRESENTATION FILE ptix-20250624_pre.xml EX-101.PRE 25170
17 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 5456
Mailing Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010
Business Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010 (212) 994-8200
Protagenic Therapeutics, Inc.\new (Filer) CIK: 0001022899 (see all company filings)

EIN.: 061390025 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-12555 | Film No.: 251088095
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)